raloxifene hydrochloride has been researched along with Endometrial Hyperplasia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JH; Kim, YJ | 1 |
| Cecchini, RS; Costantino, JP; Cronin, WM; Ford, LG; Runowicz, CD; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Bontis, J; Dinas, K; Tsalikis, T; Zafrakas, M; Zepiridis, L | 1 |
3 other study(ies) available for raloxifene hydrochloride and Endometrial Hyperplasia
| Article | Year |
|---|---|
Effects of genistein in combination with conjugated estrogens on endometrial hyperplasia and metabolic dysfunction in ovariectomized mice.
Topics: Adiposity; Animals; Diet, High-Fat; Dietary Supplements; Endometrial Hyperplasia; Endometrium; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Genistein; Glucose Intolerance; Liver; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Ovariectomy; Overweight; Phytoestrogens; Raloxifene Hydrochloride; Random Allocation; Selective Estrogen Receptor Modulators | 2015 |
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Topics: Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Hyperplasia; Estrogen Antagonists; Female; Follow-Up Studies; Hot Flashes; Humans; Incidence; Leiomyoma; Middle Aged; Ovarian Cysts; Polyps; Postmenopause; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms; Vaginal Discharge | 2011 |
Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene.
Topics: Administration, Oral; Adult; Endometrial Hyperplasia; Endometrium; Female; Humans; Osteoporosis, Postmenopausal; Polyps; Postmenopause; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Ultrasonography; Uterine Diseases; Uterine Hemorrhage | 2005 |